# Fluvastatin AmelIorates aTHerosclerosis Study

Study · id `cardio:ct-nct01681199` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01681199](<https://clinicaltrials.gov/study/NCT01681199>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01681199

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 140 participants.

## Technical summary

Registry record NCT01681199. Allocation not applicable; no masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2014-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 140 participants (planned count; ClinicalTrials.gov record NCT01681199, source copy `cardio:ctgov-nct01681199-2012-09-07`, retrieved 2026-10-31)
- Start date: 2012-07 (registry gives no type) (ClinicalTrials.gov record NCT01681199, source copy `cardio:ctgov-nct01681199-2012-09-07`, retrieved 2026-10-31)
- Primary completion: 2014-04 (anticipated) (ClinicalTrials.gov record NCT01681199, source copy `cardio:ctgov-nct01681199-2012-09-07`, retrieved 2026-10-31)
- Completion: 2014-08 (anticipated) (ClinicalTrials.gov record NCT01681199, source copy `cardio:ctgov-nct01681199-2012-09-07`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT01681199, source copy `cardio:ctgov-nct01681199-2012-09-07`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01681199-2012-09-07`, retrieved 2026-10-31)

## The registry's words

- Brief title: Fluvastatin AmelIorates aTHerosclerosis Study
- Acronym: FAITH
- Condition: Coronary Heart Disease
- Condition: Atherosclerosis
- Intervention (Drug): Fluvastatin extended release tablet
- Lead sponsor: Beijing Anzhen Hospital
- Lead sponsor class: OTHER
- Collaborator: Novartis
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: Beijing Anzhen Hospital (`cardio:org-beijing-anzhen-hospital`)
- Registry lists this organization as a collaborator: Novartis (`cardio:novartis`)

## Provenance

Content hash: 9fccf022f03a0d71900096b4edf66db51020c94a66bb50d5e45f6c0f5bc15774
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
